# A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.

> **NCT00740623** · PHASE3 · COMPLETED · sponsor: **SK Life Science, Inc.** · enrollment: 547 (actual)

## Conditions studied

- Epilepsy, Partial, Motor
- Epilepsy, Complex Partial
- Epilepsy, Simple Partial
- Focal Motor Epilepsy

## Interventions

- **DRUG:** Carisbamate
- **DRUG:** placebo
- **DRUG:** Carisbamate

## Key facts

- **NCT ID:** NCT00740623
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-10
- **Final completion:** 2010-04
- **Target enrollment:** 547 (ACTUAL)
- **Last updated:** 2013-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00740623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00740623, "A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00740623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*